Lenvatinib-induced acute acalculous cholecystitis in a patient with hepatocellular carcinoma

Kazunaga Ishigaki, Tsuyoshi Hamada, Yousuke Nakai, Yuki Ishigaki, Hiroki Oyama, Sachiko Kanai, Tatsunori Suzuki, Tomoka Nakamura, Tatsuya Sato, Ryunosuke Hakuta, Kei Saito, Tomotaka Saito, Naminatsu Takahara, Suguru Mizuno, Hirofumi Kogure, Ryosuke Tateishi, Minoru Tada, Kazuhiko Koike

研究成果: ジャーナルへの寄稿記事査読

3 被引用数 (Scopus)

抄録

The patient was a 67-year-old man with advanced hepatocellular carcinoma (HCC) due to chronic hepatitis B. Due to refractoriness to radiofrequency ablation and transcatheter arterial chemoembolization, lenvatinib, a new oral mutikinase inhibitor, was started with a daily dose of 12 mg. However, on day 6 the patient developed acute-onset, right upper quadrant pain associated with fever; laboratory tests revealed leukocytosis and liver dysfunction. CT scan showed the swollen gallbladder with wall thickening with no evidence of gallstones, and the diagnosis of acute acalculous cholecystitis was made. After the resolution of cholecystitis by antibiotics and endoscopic nasogallbladder drainage placement, lenvatinib was resumed at a reduced daily dose of 4 mg. However, acute acalculous cholecystitis recurred, supporting lenvatinib as a cause of acute acalculous cholecystitis. Using the Naranjo adverse drug reaction probability scale, a score of 6 was derived, which indicates that this adverse event was probably caused by lenvatinib. In summary, we present a patient with advanced HCC who underwent repeated episodes of acute acalculous cholecystitis as a rare adverse event associated with lenvatinib.

本文言語英語
ページ(範囲)568-571
ページ数4
ジャーナルClinical Journal of Gastroenterology
13
4
DOI
出版ステータス出版済み - 1 8月 2020
外部発表はい

フィンガープリント

「Lenvatinib-induced acute acalculous cholecystitis in a patient with hepatocellular carcinoma」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル